A week after reaching a $270 million settlement Oklahoma’s attorney some claims dropped in an effort to induce them to pay the cost of the nation’s deadly financial crisis in its lawsuit against other drugmakers.

Attorney General Mike Hunter’s division filed a motion that destroys claims of fraud and deceit, unjust enrichment and violations of the nation’s Medicaid laws against a dozen drugmakers. Hunter said dismissing those claims does not lessen the amount of damages that the state is looking for.

Hunter’s office will continue to pursue allegations that the companies created will be the most important allegation from the drugmakers.

“We’re definitely going to be prepared for trial, and we are going to hold those defendants responsible for the harm they’ve done to the nation and its citizens,” Hunter said.

Opioids, such as heroin and prescription drugs, were a element in a listing 48,000 deaths across the U.S. at 2017, according to the Centers for Disease Control and Prevention. About 400 deaths were listed by oklahoma that year.

Nuisance claims are contained in several authorities’ instances against drugmakers, said attorney. The law firm is representing Georgia and Alabama in opioid litigation that is nationwide and isn’t affiliated with the lawsuit of Oklahoma.

Authorities are currently using public claims to attempt to recover the expense of treatment, deaths and crime linked to opioid abuse,” Allen said. Lawyers representing instances are closely watching Oklahoma’s.

“If there’s a plaintiff’s verdict in one instance, then drives the value of all the other cases,” he explained.

Sabrina Powerful, an attorney for Johnson & Johnson and its subsidiaries, which are one of the firms being sued, explained in a statement that dismissal of the claims demonstrates they were groundless.

“We shall continue to shield against the staying portion of the unsubstantiated allegations,” Strong said. Trial of this nation’s lawsuit is scheduled to start on May 28 at Norman, roughly 17 miles (27 km ) south of Oklahoma City.

Other defendants in the case include Ireland-based Allergan Dublin and New Jersey-based Teva Pharmaceuticals USA.

By ignoring all also the public nuisance claim, Hunter reported the movement of the state is going to result in a bench trial before a judge rather than a jury. The companies have until Tuesday to respond to the nation’s motion.

Hunter said trying the case before a judge and not a jury provide both sides time and ought to lower the number of pretrial motions filed with both firms.

“We’ve got a handful of attorneys and they’ve got hundreds, so it was a significant strategic decision with regard to preparing for trial,” Hunter explained.

Allegations settled on March 26 from the very first such agreement following a wave of nearly 2,000 lawsuits against the business who had threatened to shove it into bankruptcy against drugmaker Purdue Pharma for $270 million.

Almost $200 million goes toward developing a National Center for Addiction Studies and Treatment at Oklahoma State University at Tulsa, while local governments will get $12.5 million.

However, Hunter stated the law does not apply since his office not technically received the settlement money, per Purdue Pharma’s fantasies.


This edition of the story corrects the town in Alabama to Montgomery from the 6th paragraph.


Associated Press writers Sean Murphy and Adam Kealoha Causey in Oklahoma City contributed to this report.